Prot #CC-92480-MM-002: A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory

Project: Research project

Project Details

StatusActive
Effective start/end date11/14/1911/14/22

Funding

  • Celgene Corporation (Prot #CC-92480-MM-002)